Use of cardiac troponin T levels as an indicator of doxorubicin-induced cardiotoxicity.
The release of cardiac troponin T (cTnT) as a biomarker of doxorubicin-induced chronic cardiac injury was evaluated in the spontaneously hypertensive rat (SHR) model. Elevations in serum levels of cTnT and decreased immunohistochemical staining of heart sections for this protein were noted in SHRs treated with cumulative doses of doxorubicin (7 mg/kg) that induced only minimal histological alterations in myocytes. Concentrations of cTnT were further elevated, coincident with reduced immunohistochemical staining, in SHRs given 10-12 mg/kg doxorubicin. Thus, monitoring serum levels of cTnT can detect doxorubicin-induced myocyte damage in SHR and may prove useful for the noninvasive evaluation of this toxicity in humans.
Herman
E H
EH
Division of Applied Pharmacological Research, Food and Drug Administration, Laurel, Maryland 20908, USA.
Lipshultz
S E
SE
Rifai
N
N
Zhang
J
J
Papoian
T
T
Yu
Z X
ZX
Takeda
K
K
Ferrans
V J
VJ
D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000633:toxicity*; D015415:Biomarkers / Q000097:blood; D004195:Disease Models, Animal; D004317:Doxorubicin / Q000633:toxicity*; D019084:Fluorescent Antibody Technique, Indirect; D006321:Heart / Q000187:drug effects*; D006331:Heart Diseases / Q000097:blood* / Q000139:chemically induced / Q000473:pathology; D006973:Hypertension / Q000097:blood; D009206:Myocardium / Q000378:metabolism; D051381:Rats; D011918:Rats, Inbred SHR; D014336:Troponin / Q000097:blood*; D020107:Troponin T
D000903:Antibiotics, Antineoplastic; D015415:Biomarkers; D014336:Troponin; D020107:Troponin T; D004317:Doxorubicin